Quick Answer
Esperion Therapeutics, Inc. reported Cash and Equivalents of $167.85 million for fiscal year 2025.
Esperion Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $167.85M | +16.0% |
| 2024 | $144.76M | +76.0% |
| 2023 | $82.25M | -34.1% |
| 2022 | $124.78M | -40.3% |
| 2021 | $208.89M | -31.5% |
| 2020 | $304.96M | +83.6% |
| 2019 | $166.13M | +349.3% |
| 2018 | $36.97M | +7.3% |
| 2017 | $34.47M | -9.7% |
| 2016 | $38.16M | -50.7% |
| 2015 | $77.34M | -9.1% |
| 2014 | $85.04M | +50.4% |
| 2013 | $56.54M | +768.2% |
| 2012 | $6.51M | +314.5% |
| 2011 | $1.57M | -54.0% |
| 2010 | $3.41M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $92.45M | -36.1% | +7.4% |
| June 30, 2025 | $86.06M | -54.5% | -24.9% |
| March 31, 2025 | $114.63M | -49.4% | -20.8% |
| December 31, 2024 | $144.76M | +76.0% | +0.0% |
| September 30, 2024 | $144.72M | +26.0% | -23.6% |
| June 30, 2024 | $189.30M | +36.7% | -16.5% |
| March 31, 2024 | $226.61M | +56.4% | +175.5% |
| December 31, 2023 | $82.25M | -34.1% | -28.4% |
- Esperion Therapeutics, Inc. showed an increase of +16.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Esperion Therapeutics, Inc.’s cash and equivalents has grown by 4815.3% (from $3.41 million to $167.85 million).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: